If you have malignant melanoma that has spread to other areas, your healthcare provider may prescribe DTIC-Dome. This medication can also be used in combination with other medications to treat Hodgkin's disease. It is given as an injection into a vein (intravenously, or by IV) once daily for 5 to 10 days, followed by a break in treatment. Side effects include nausea, vomiting, and loss of appetite.
DTIC-Dome® (dacarbazine) is a prescription chemotherapy medication. It is approved to treat a type of skin cancer known as malignant melanoma that has spread to other areas of the body (metastasized). It is also approved for use in combination with other medications to treat Hodgkin's disease (also known as Hodgkin's lymphoma). DTIC-Dome is also sometimes referred to simply as DTIC.
DTIC-Dome was originally made by Bayer Healthcare. However, the medication is no longer available in brand-name form. Several companies make a generic version.
It is not entirely known how DTIC-Dome works to treat cancer. It is classified as an alkylating agent. Alkylating agents are medications that transfer a piece of their structure, called an alkyl group, to DNA. This causes the strands of DNA to bond to each other and become linked (known as "cross-linking"). The linked strands are unable to uncoil and separate, which is necessary for the DNA to replicate.
DTIC-Dome may also work by incorporating itself into DNA and interfering with the ability of the DNA to replicate. Because DNA replication is essential for cells to grow and multiply, DTIC-Dome may prevent cancer cells from growing and multiplying.